about
Obesity and Its Potential Effects on Antidepressant Treatment Outcomes in Patients with Depressive Disorders: A Literature ReviewAMIGO2, a novel membrane anchor of PDK1, controls cell survival and angiogenesis via Akt activation.A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical dataTargeting PI3K/Akt represses Hypoxia inducible factor-1α activation and sensitizes Rhabdomyosarcoma and Ewing's sarcoma cells for apoptosisRealizing the promise of cancer predisposition genes.Assessment of efficacy, safety and quality of life of 55 patients with metastatic renal cell carcinoma treated with temsirolimus: a single-center experience in Japan.Regulation of blood-testis barrier (BTB) dynamics during spermatogenesis via the "Yin" and "Yang" effects of mammalian target of rapamycin complex 1 (mTORC1) and mTORC2.miR-221/222 control luminal breast cancer tumor progression by regulating different targets.Caught in the AKT: identification of a de novo pathway in MCAP and MPPH and its therapeutic implications.Comparison of Intracellular Stress Response of NCI-H526 Small Cell Lung Cancer (SCLC) Cells to Platinum(II) Cisplatin and Platinum(IV) Oxoplatin.Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.Genome-wide and gene-based association studies of anxiety disorders in European and African American samplesHepatocyte growth factor increases vascular endothelial growth factor-A production in human synovial fibroblasts through c-Met receptor pathway.Dysregulation of RNA polymerase I transcription during disease.Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.The differential susceptibilities of MCF-7 and MDA-MB-231 cells to the cytotoxic effects of curcumin are associated with the PI3K/Akt-SKP2-Cip/Kips pathway.Activation of 3-phosphoinositide-dependent kinase 1 (PDK1) and serum- and glucocorticoid-induced protein kinase 1 (SGK1) by short-chain sphingolipid C4-ceramide rescues the trafficking defect of ΔF508-cystic fibrosis transmembrane conductance regulaIncidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysisCholangiocarcinoma: molecular pathways and therapeutic opportunitiesCancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma.Broad-scale phosphoprotein profiling of beta adrenergic receptor (β-AR) signaling reveals novel phosphorylation and dephosphorylation eventsEffects of microwave radiation on brain energy metabolism and related mechanisms.MicroRNA-200 promotes lung cancer cell growth through FOG2-independent AKT activation.Signal transduction via the T cell antigen receptor in naïve and effector/memory T cells.TDRG1 functions in testicular seminoma are dependent on the PI3K/Akt/mTOR signaling pathwayPIK3CA mutation detection in metastatic biliary cancer using cell-free DNAThe mTOR inhibitor AZD8055 inhibits proliferation and glycolysis in cervical cancer cellsp110δ PI3 kinase pathway: emerging roles in cancer.Phosphatidylinositol 3-phosphates-at the interface between cell signalling and membrane traffic.Protumor activities of the immune response: insights in the mechanisms of immunological shift, oncotraining, and oncopromotion.Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance.A dual PI3K/AKT/mTOR signaling inhibitor miR-99a suppresses endometrial carcinoma.Critical Points in Tumorigenesis: A Carcinogen-Initiated Phase Transition Analyzed via Single-Cell Proteomics.Celecoxib inhibits insulin-like growth factor 1 induced growth and invasion in non-small cell lung cancerSynergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling.Icariside II, a natural mTOR inhibitor, disrupts aberrant energy homeostasis via suppressing mTORC1-4E-BP1 axis in sarcoma cellsClinicopathological feature and prognosis of primary hepatic gastrointestinal stromal tumor.Notch4 inhibition reduces migration and invasion and enhances sensitivity to docetaxel by inhibiting Akt/fascin in pancreatic cancer cells.Clinicopathological features and prognosis of coexistence of gastric gastrointestinal stromal tumor and gastric cancer
P2860
Q26771735-00D6748F-AD1E-4D25-B7D3-3A1A7868B373Q27309773-9ADAAFC7-68F6-4C05-9115-B1EC05094737Q27851995-F3EAA9F8-8FEB-4F74-9915-2F092A2F5E9DQ28247338-8095A742-828A-45CC-B355-6540112AE9FDQ28397404-BB0FF25C-AF1B-419C-81E0-E024D9B3B069Q30743260-9DE9B40D-4A72-4FB9-928E-A7A58A43CDA1Q33410223-9AEE60A3-16FA-4809-953A-277B241A15B7Q33863571-DCB13DF0-1C27-4B2C-82BF-21C70BAA68B0Q33952998-7F9BF0C0-401A-4A93-BD4D-4B9B3CC070E9Q34300451-68F849CA-4108-4551-B411-3DAC0DB19B06Q34309915-FFD7E8A9-A236-4316-BF5E-63E64B150FD1Q34372987-65491368-B11B-466C-A419-F4F42DEF8A73Q34447563-4B7431F2-1595-4F4E-BFD4-C52CB1C00DE8Q34500778-F5052F6F-02FA-4C22-B84A-DF875EE6D532Q34645436-4DC2317E-95DB-471F-A46C-C3200E18E372Q34732945-1D9638BB-5C37-4D4D-AE75-6845E3879461Q34746718-3039A19B-56D5-4323-A8B9-BDB8BB54FB06Q34774491-CE817E65-84BC-44C1-9E91-DDA2A9E9B0B3Q34778631-8CB54FAD-C57C-43A5-A04E-8FCB09014948Q34959174-3C0D7F09-F161-4803-95A3-36D8C5E47422Q35035236-AE2B930D-C047-4593-A662-963A1D9FAB5AQ35067711-2F0B83AC-16EB-41BE-9C2A-EF186DD4A143Q35633804-2CE22811-EE6A-4DDA-B079-F0683C17C730Q36319557-6FDB7E40-E128-405D-859A-C2D5B3CCFDA2Q36495930-357D890C-1584-4AAF-A36C-9DC1DAFDF5F8Q36498943-F102B988-B1B5-4F57-9FDE-97D17EE15305Q36545534-3237564A-54C2-45E9-9656-9970D24F3C1EQ36611732-249EC74B-4C33-4C7F-A48D-86186484851FQ36647928-7825BB9F-1E68-4E89-A757-0DCF211F9B8AQ36712621-B35E3D33-5167-452C-9F09-0C0C8C7266C3Q36729107-E60AAE0F-9BE2-4662-8413-3D75C6807B32Q36815271-FFFE1C62-5EC9-4B7A-BB46-1C2EEA89C1C1Q36841237-19758467-1352-41B8-996D-B6CD7148D43BQ36950815-C71C5CFC-E745-4078-9FC8-BA220252696BQ36981423-FC5927FB-B3E1-4D43-A86C-1A0BD54EFCEAQ37040669-B377A2A8-D4B0-44D0-AF0E-1A4229BBD2F5Q37317409-03698194-EC97-4EF9-B54D-BFA479A35960Q37321003-E8947E5B-3BAD-43CA-A3FB-D7F89694C61DQ37407037-3F248FC4-802B-4770-9927-2C35FF24764CQ37409592-2AF13177-C316-48F7-84FB-82F65EA3DFFC
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Targeting PI3 kinase/AKT/mTOR signaling in cancer.
@en
Targeting PI3 kinase/AKT/mTOR signaling in cancer.
@nl
type
label
Targeting PI3 kinase/AKT/mTOR signaling in cancer.
@en
Targeting PI3 kinase/AKT/mTOR signaling in cancer.
@nl
prefLabel
Targeting PI3 kinase/AKT/mTOR signaling in cancer.
@en
Targeting PI3 kinase/AKT/mTOR signaling in cancer.
@nl
P2093
P1476
Targeting PI3 kinase/AKT/mTOR signaling in cancer
@en
P2093
Benjamin Solomon
Karen Sheppard
Kathryn M Kinross
P356
10.1615/CRITREVONCOG.V17.I1.60
P407
P577
2012-01-01T00:00:00Z